Expert Interview
A look at how prescribing patterns will be affected for patients with high cholesterol after FDA clearance for 23andMe’s genetic reports to include predicted patient reaction to simvastatin based on SLCO1B1 genotype.
Ticker(s): MEInstitution: Self-employed
- Family Medicine physician practicing in a large suburban setting in Texas for over 20 years
- treats 600 patients for high cholesterol
- Can discuss how a patient's SLCO1B1 genotype could affect their response to simvastatin and what other options are available for those patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
